Intended for healthcare professionals


Priadel: bipolar drug will remain on market after new price is agreed by government

BMJ 2020; 371 doi: (Published 25 November 2020) Cite this as: BMJ 2020;371:m4603
  1. Elisabeth Mahase
  1. The BMJ

Priadel, a brand of lithium widely used to treat bipolar disorder, will remain on the market after a new deal was struck between the manufacturer Essential Pharma and the Department for Health and Social Care (DHSC).

The drug company previously announced that it would withdraw Priadel in April 2021. This led the Competition and Markets Authority (CMA) to launch an investigation into whether the company had “abused its dominant position” in order to get patients to …

View Full Text

Log in

Log in through your institution


* For online subscription